CDC2-like (CLK) protein kinase inhibition as a novel targeted therapeutic strategy in prostate cancer
Abstract Dysregulation of alternative splicing is a feature of cancer, both in aetiology and progression. It occurs because of mutations in splice sites or sites that regulate splicing, or because of the altered expression and activity of splice factors and of splice factor kinases that regulate spl...
Main Authors: | Simon Uzor, Sean R. Porazinski, Ling Li, Bethany Clark, Masahiko Ajiro, Kei Iida, Masatoshi Hagiwara, Abdullah A. Alqasem, Claire M. Perks, Ian D. Wilson, Sebastian Oltean, Michael R. Ladomery |
---|---|
Format: | Article |
Language: | English |
Published: |
Nature Portfolio
2021-04-01
|
Series: | Scientific Reports |
Online Access: | https://doi.org/10.1038/s41598-021-86908-6 |
Similar Items
-
Hypoxia leads to significant changes in alternative splicing and elevated expression of CLK splice factor kinases in PC3 prostate cancer cells
by: Elizabeth Bowler, et al.
Published: (2018-04-01) -
Clk/STY (cdc2-like kinase 1) and Akt regulate alternative splicing and adipogenesis in 3T3-L1 pre-adipocytes.
by: Pengfei Li, et al.
Published: (2013-01-01) -
Kinase domain insertions define distinct roles of CLK kinases in SR protein phosphorylation.
by: Bullock, A, et al.
Published: (2009) -
Kinase domain insertions define distinct roles of CLK kinases in SR protein phosphorylation
by: Bullock, A, et al.
Published: (2009) -
PDIVAS: Pathogenicity predictor for Deep-Intronic Variants causing Aberrant Splicing
by: Ryo Kurosawa, et al.
Published: (2023-10-01)